Antares Pharma, Inc. (Antares) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The Company’s subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares has a multi-product deal with Teva Pharmaceutical Industries, Ltd. (Teva) that includes Tev-Tropin human growth hormone and has partnerships with Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR) that include their human growth hormone (hGH) products. In the gel-based area, its lead product candidate, Anturol, an oxybutynin Advanced Transdermal Delivery (ATD) gel for the treatment of overactive bladder (OAB), was under evaluation in a Phase III trial as of December 31, 2009.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSE:AIS
- CUSIP: N/A
- Web: N/A
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: N/A
Dividend:
Frequently Asked Questions for Antares Pharma (NYSE:AIS)
What is Antares Pharma's stock symbol?
Antares Pharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIS."
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Partnership Assurance Group PLC (PA), Celgene (CELG), GlaxoSmithKline plc (GSK), Thermo Fisher Scientific (TMO), Biogen (BIIB), AstraZeneca plc (AZN), Baxter International (BAX), Shire PLC (SHP), Alexion Pharmaceuticals (ALXN), Laboratory Corp. of America Holdings (LH), Hospira (HSP), Smith & Nephew plc (SN), Universal Health Services (UHS), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), United Therapeutics (UTHR), ConvaTec Group PLC (CTEC) and Mediclinic International PLC (MDC).
How do I buy Antares Pharma stock?
Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
MarketBeat Community Rating for Antares Pharma (NYSE AIS)MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Antares Pharma (NYSE:AIS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Antares Pharma (NYSE:AIS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Antares Pharma (NYSE:AIS)Earnings History by Quarter for Antares Pharma (NYSE AIS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/13/2013 | Q4 12 | ($0.03) | ($0.04) | | | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for Antares Pharma (NYSE:AIS)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Antares Pharma (NYSE:AIS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Antares Pharma (NYSE:AIS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Antares Pharma (NYSE:AIS)
Latest Headlines for Antares Pharma (NYSE:AIS)
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Antares Pharma (AIS) Chart for Wednesday, August, 23, 2017
